64Cu-DOTA-Panitumumab

N/A

Report date: 2025/11/11 18:00:02

Base Information

Drug Name64Cu-DOTA-Panitumumab

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Copper > 64CuRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsSquamous Cell Carcinoma of Head and Neck

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNational Center for Biotechnology Information

China Registration ClassN/A

Develop Information

Active CompaniesNational Center for Biotechnology Information

Inactive CompaniesN/A

Active IndicationsSquamous Cell Carcinoma of Head and Neck

Inactive IndicationsN/A

Other Information

ATC CodeN/A